Multicenter, Randomized, Non-comparative, Phase II Trial on the Efficacy and Safety of the Combination of Bevacizumab and Trabectedin With or Without Carboplatin in Adult Women With Platinum Partially Sensitive Recurring Ovarian Cancer
Latest Information Update: 25 Jul 2022
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Trabectedin (Primary) ; Carboplatin
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2019 Status changed from active, no longer recruiting to completed.
- 20 Sep 2019 Results published in the British Journal of Cancer
- 24 Oct 2018 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.